In what appears to be a strategic move to diversify its business, Alphabet Inc has relaunched its Life Sciences division as a new spinoff company known as Verily. In an introductory video, former Google showed that Verily will be focusing more on health sciences and how it will provide solutions or studies to combat or manage diseases, the Verge notes. Its standalone website, verily.com, is also live as well.
"As a life sciences team within Google[x], we were able to combine the best of our technology heritage with expertise from across many fields. Now, as an independent company, Verily is focused on using technology to better understand health, as well as prevent, detect, and manage disease," the website read.
Endgadget said that the new Verily is working on more wearables, among other projects, to achieve their goals. One goal is reportedly using wearables to detect cancer cells at very early stages in patients. Verily is also targeting to partner with third-party firms who have the technology to help the former achieve its goals.


TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat
Taiwan Activates Backup Communications After Undersea Cable Break on Dongyin Island
FBI Warns of China’s Expanding Hack-for-Hire Network Amid Extradition Case
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 



